3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
HhAntag691
11
sonidegib
5
cemiplimab
5
methyl 5-aminolevulinate
4
daromun
4
Imiquimod
3
IPI-926
3
gusacitinib
2
Photochemotherapy
2
Drug Evaluation
2
3-ingenyl angelate
2
tozuleristide
1
silmitasertib
1
pembrolizumab
1
TAK-441
1
NVP-LEQ506
1
MAPRE1 protein, human
1
Intravital Microscopy
1
Interleukin-2
1
Injections
1
IFL protocol
1
Folfox protocol
1
Capecitabine
1
Bevacizumab
1
BO-112
1
BMS-833923
1
BF-200 ALA
1
Ascorbic Acid
1
Aminolevulinic Acid
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Basal Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled